BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» OX-425 shows safety and robust antitumor efficacy in cancer models
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
OX-425 shows safety and robust antitumor efficacy in cancer models
March 10, 2023
No Comments
Researchers from Onxeo SA presented preclinical data for OX-425, a first-in-class oligodeoxynucleotide that operates as a poly (ADP-ribose) polymerase 1 (PARP-1) decoy, and which is being developed as anticancer agent.
BioWorld Science
Conferences
Cancer